Holen Sie sich die Stockscreener-App
138.40
0.39%
-0.54
Schlusskurs vom Vortag:
$138.94
Offen:
$138.94
24-Stunden-Volumen:
1.15M
Relative Volume:
0.92
Marktkapitalisierung:
$14.07B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$668.60M
KGV:
21.28
EPS:
6.5044
Netto-Cashflow:
$831.30M
1W Leistung:
-5.35%
1M Leistung:
-9.76%
6M Leistung:
+5.54%
1J Leistung:
-1.77%
1-Tages-Spanne:
$137.02
$138.94
1-Wochen-Bereich:
$137.00
$146.26
52-Wochen-Spanne:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
138.40 | 14.07B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance UK
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - stocktwits.com
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Eastern Progress
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - Eastern Progress
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - webull.com
Neurocrine Biosciences stock draws support from strong Q2 figures - AD HOC NEWS
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story - Yahoo Finance
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost - Kalkine Media
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com Nigeria
Neurocrine Biosciences Inc (NBIX) Shares Fall 4.6% -- What GF Sc - GuruFocus
Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) director logs 14,343-share vesting, 7,839 withheld for taxes - Stock Titan
Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - stocktitan.net
Neurocrine Biosciences (NBIX) grants HR chief 3,587 shares - Stock Titan
PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares - stocktitan.net
CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests - Stock Titan
Is Neurocrine Biosciences (NBIX) Still Undervalued As It Heads Into September Conferences? - simplywall.st
Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan
Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria
How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st
Neurocrine (NBIX) director donates 1,000 shares - Stock Titan
Neurocrine Biosciences Inc. (NBIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September - PR Newswire
Resilient Neurocrine Biosciences stock holds firm as Crenessity sales surge and valuation stretches - AD HOC NEWS
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation - ChartMill
Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount? - simplywall.st
How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data - Sahm
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - Yahoo Finance
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition - Yahoo Finance
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 38.67% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):